(On account of Higher spends on R&D) We expect Total Expense growth to be 12.2% in 2019. Total Expense for Rapt Therapeutics substantially increased from $29.1 Mil in 2017 to $36.1 Mil in 2018 an increase of 24.1%. Since the company is still in its initial stage of research & development and the company has not commercialized any drug, there are no revenues. First drug of the company is expected to be launched after 2020Ī closer look At Rapt Therapeutics’ Total Expenses over the last few years and the outlook